1. Bókkon I, Vas JP, Császár N, Lukács T. Challenges to free will: transgenerational epigenetic information, unconscious processes, and vanishing twin syndrome. Rev Neurosci 2014;25:163-75.
3. Gjerris AC, Loft A, Pinborg A, Christiansen M, Tabor A. The effect of a ‘vanishing twin’ on biochemical and ultrasound first trimester screening markers for Down’s syndrome in pregnancies conceived by assisted reproductive technology. Hum Reprod 2009;24:55-62.
4. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins. Screening for fetal chromosomal abnormalities: ACOG practice bulletin, number 226. Obstet Gynecol 2020;136:e48-69.
5. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001-11.
6. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 2003;110:276-80.
7. Huang T, Boucher K, Aul R, Rashid S, Meschino WS. First and second trimester maternal serum markers in pregnancies with a vanishing twin. Prenat Diagn 2015;35:90-6.
9. Handschuh K, Guibourdenche J, Guesnon M, Laurendeau I, Evain-Brion D, Fournier T. Modulation of PAPP-A expression by PPARgamma in human first trimester trophoblast. Placenta 2006;27(Suppl A):S127-34.
10. Chasen ST, Perni SC, Predanic M, Kalish RB, Chervenak FA. Does a “vanishing twin” affect first-trimester biochemistry in Down syndrome risk assessment? Am J Obstet Gynecol 2006;195:236-9.
14. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999;19:1035-42.
15. Snijders R, Smith E. The role of fetal nuchal translucency in prenatal screening. Curr Opin Obstet Gynecol 2002;14:577-85.
16. Lee SW. Prenatal maternal serum screening for fetal aneuploidy. J Korean Medical Assoc 2015;58:989-94.
17. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886-94.
18. Benn PA. Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing. Clin Chim Acta 2002;323:1-16.
19. Chen HJ, Huang LW, Lin YH, Seow KM, Hsieh BC, Hwang JL, et al. Midtrimester maternal serum inhibin A levels after multifetal pregnancy reduction. Prenat Diagn 2007;27:431-4.
20. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. Br J Obstet Gynaecol 1988;95:330-3.
21. Lee S, Jung Y, Jisu S, Han Y, Kim M, Shim J, et al. EP07. 01: the effect of vanishing twin on the first and second trimester maternal serum makers and nuchal translucency: a multicentre prospective cohort study. Ultrasound Obstet Gynecol 2018;52:219-20.
22. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623-30.
26. Hopkins MK, Dugoff L. Screening for aneuploidy in twins. Am J Obstet Gynecol MFM 2022;4:100499.
28. Audibert F, Gagnon A. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies. J Obstet Gynaecol Can 2011;33:754-67.
29. Curnow KJ, Wilkins-Haug L, Ryan A, Kırkızlar E, Stosic M, Hall MP, et al. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. Am J Obstet Gynecol 2015;212:79e1-9.
30. Balaguer N, Mateu-Brull E, Serra V, Simón C, Milán M. Should vanishing twin pregnancies be systematically excluded from cell-free fetal DNA testing? Prenat Diag 2021;41:1241-8.